| Hazard Information | Back Directory | [Uses]
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer[1][2]. | [in vivo]
Ociperlimab (BGB-A1217; 3 and 10 mg/kg; i.p.; CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice) elicits anti-tumor efficacy in an Fc-dependent manner[1]. | Animal Model: | CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice[1] | | Dosage: | 3 and 10 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Inhibited tumor growth compared to the single agent treatment groups. |
| [References]
[1] Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319. DOI:10.3389/fimmu.2022.828319
[2] Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26. DOI:10.1007/s11033-022-08220-4 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|